company background image
WINT

Windtree Therapeutics NasdaqCM:WINT Stock Report

Last Price

US$0.32

Market Cap

US$9.8m

7D

3.1%

1Y

-84.0%

Updated

28 Sep, 2022

Data

Company Financials +
WINT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

WINT Stock Overview

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases.

Windtree Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Windtree Therapeutics
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$2.37
52 Week LowUS$0.28
Beta0.29
1 Month Change-21.32%
3 Month Change-23.19%
1 Year Change-83.99%
3 Year Change-97.15%
5 Year Change-97.29%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

WINTUS BiotechsUS Market
7D3.1%2.9%-2.0%
1Y-84.0%-24.2%-20.3%

Return vs Industry: WINT underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: WINT underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is WINT's price volatile compared to industry and market?
WINT volatility
WINT Average Weekly Movement19.8%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: WINT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: WINT's weekly volatility has increased from 13% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199233Craig Fraserhttps://windtreetx.com

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company’s lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.

Windtree Therapeutics, Inc. Fundamentals Summary

How do Windtree Therapeutics's earnings and revenue compare to its market cap?
WINT fundamental statistics
Market CapUS$9.81m
Earnings (TTM)-US$46.75m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
WINT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$17.79m
Gross Profit-US$17.79m
Other ExpensesUS$28.96m
Earnings-US$46.75m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.53
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio83.4%

How did WINT perform over the long term?

See historical performance and comparison